FOXP3 and neoplasm: In addition to enhancing T cell priming through blockade of inhibitory interactions between antigen presenting cells and T cells38, anti-CLTA-4 therapy may also deplete T regulatory FOXP3+ cells in the tumor microenvironment39–41.